Traditional Chinese Medicine (TCM) Colon Dialysis Treats Non-dialysis End-Stage Kidney Disease
Clinical Observation of Therapeutic Effects on Traditional Chinese Medicine Colon Dialysis Treating Non-dialysis End-Stage Kidney Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Patients who would hospitalized in Nephrology of Guangdong Provincial Hospital of Traditional Chinese Medicine have chance to participate this study. All participates will be divided into two groups depending on their individual treatment interests and the baseline information will be balanced.
Integrated Therapy is routine symptomatic and supportive treatment for CRF,including reducing blood pressure and urine protein, improving anemia,regulating calcium and phosphorus metabolism and so on.The colon lotion used in colonic dialysis is a kind of hospital preparation. It consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The whole treatment lasts about 10 days,as long as a regular drill-and-fill procedure. Before and after the treatment, related body dimensions will be tested.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Pang Peng
- Phone Number: 01186-15099960366
- Email: pangpeng@stu2014.jnu.edu.cn
Study Contact Backup
- Name: Chen X Yin, Ph.D
- Phone Number: 01186-13822263950
- Email: tchenxiaoyin@jnu.edu.cn
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510006
- Recruiting
- Guangdong Provincial Hospital of Traditional Chinese Medicine
-
Contact:
- Kun Bao
- Email: baokun@aliyun.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1.corresponding to diagnosis standards of CKD-5:eGFR≤15ml/min/1.73m2; 2. did not receive kidney replacement therapy; 3. no gastrointestinal diseases (including ulcerative colitis, irritable bowel syndrome, inflammation, cancer, infection, bleeding, etc.) in the past 1 year; 4.not associated with rectal-related disorders (hemorrhoids, anal fistula, rectal cancer, cancer, infection, bleeding, etc.); 5.Sign informed consent.
Exclusion Criteria:
- 1. having used antibiotics, hormones, immunosuppressive, probiotics and laxatives in past three months; 2. pregnant or lactating patients; 3.cannot cooperate or tolerate colonic dialysis treatment; 4.combined with active stage of malignant tumors, cardiovascular, respiratory system, decompensated liver cirrhosis or blood system diseases (including coagulation disorders, hematopoietic dysfunction, etc.) and other serious primary disease; 5. recent merger of patients with infectious diseases; 6.having known to be allergic to some drugs in the study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
No Intervention: Integrated Therapy
This arm is an control group,in which participants will receive conventional integrated therapy on CRF.
|
|
|
Experimental: Integrated Therapy and colonic dialysis
This arm is a treatment group,in which participants will receive integrated therapy on CRF and traditional Chinese medicine Colonic dialysis with traditional Chinese medicine colon lotion once a day.
|
The colon lotion used in this clinic trial is a kind of hospital preparation.
It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of glomerular filtration rate index
Time Frame: the first day before intervention and the eleventh day
|
measuring the level of urea nitrogen,blood urea nitrogen,serum creatinine, serum cystatin C, blood and urineβ2-microglobulin.
calculating the creatinine clearance rate.
|
the first day before intervention and the eleventh day
|
|
Change of intestinal flora
Time Frame: the first day before intervention and the eleventh day
|
measuring serum endotoxin and investigating the differences of intestinal flora between control group and experience group,as well as the differences between before colonic dialysis and after colonic dialysis.
|
the first day before intervention and the eleventh day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change of serum electrolyte changes
Time Frame: the first day before intervention and the eleventh day
|
measuring serum contents of sodium,potassium and phosphorus.
|
the first day before intervention and the eleventh day
|
|
Change of related inflammatory index
Time Frame: the first day before intervention and the eleventh day
|
measuring hs-C reactive protein(hs-CRP),interleukin 1β(IL-1β),IL-6,tumor necrosis factor α(TNF-α) in serum.
|
the first day before intervention and the eleventh day
|
|
Change of renal fibrosis index
Time Frame: the first day before intervention and the eleventh day
|
measuring platelet derived growth factor (PDGF) secretion and serum transforming growth factor β(TGF-β).
|
the first day before intervention and the eleventh day
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Chen X Yin, Ph.D, Jinan University Guangzhou
- Study Director: Bao Kun, Guangdong Provincial Hospital of Traditional Chinese Medicine
- Principal Investigator: Pang Peng, Jinan University Guangzhou
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CRF-CD2017
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on End-Stage Kidney Disease
-
NCT01921933CompletedEnd-stage Renal Disease | End-stage Kidney Disease
-
NCT07507981CompletedHemodialysis | End Stage Cronic Kidney Disease
-
NCT02392208CompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney Disease
-
NCT02694068CompletedEnd-Stage Kidney Disease
-
NCT00062699Terminated
-
NCT02342119CompletedEnd-stage Kidney Disease
-
NCT02338635UnknownEnd-Stage Kidney Disease
-
NCT00143741CompletedEnd-Stage Kidney Disease
-
NCT04912050CompletedAcute Kidney Injury | End Stage Renal Disease (ESRD) | End Stage Renal Disease on Dialysis
-
NCT05703633Not yet recruiting
Clinical Trials on colon lotion
-
NCT02462122CompletedPlaque Psoriasis
-
NCT02849860Completed
-
NCT02462070CompletedPlaque Psoriasis
-
NCT02142959Completed
-
NCT01882647Completed
-
NCT01871402Completed
-
NCT03002571Completed
-
NCT05786976CompletedEczema-Prone Skin | Atopic Diathesis
-
NCT02062060Completed